ClinicalTrials.gg
Active, not recruitingNCT06183931DepleTTR-CMUpdated Oct 22, 2026

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

A Phase 3 interventional study of ALXN2220 and Placebo in Transthyretin Amyloid Cardiomyopathy, sponsored by Alexion Pharmaceuticals, Inc.. Active, not recruiting at 213 sites in 27 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Updated Oct 22, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,182
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 141 studies in Amyloidosis with a site in United States — 39 open to participants now, 47 under way, 10 of them phase 3. Amyloidosis · United States.

Enrollment
6th of 99
1,182 · median 45
Started
2024
with 6 others
Phase 3
27 of 141
7 open now
Primary completion
2027-12
later than 25 of 46 live
Registered
117th of 141
by date

Among the 141 studies in Amyloidosis with a site in United States, this one is the 6th largest by enrollment of the 99 interventional ones that give a count, is one of 7 that started in 2024, is one of 27 in phase 3, reaches primary completion later than 25 of the 46 other live ones, and was the 117th registered.

Amyloidosis

290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.

Browse Amyloidosis studies →

Open to participants now

39 of the 141 studies in Amyloidosis with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 141 studies in Amyloidosis with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular (CV) clinical events.

03

Conditions studied

  • Transthyretin Amyloid Cardiomyopathy

Browse trials for

Keywords

  • Amyloid Depleter
  • ALXN2220
  • All-cause mortality (ACM)
  • Cardiovascular (CV)
  • Transthyretin Amyloid Cardiomyopathy
  • Transthyretin amyloid (ATTR)
  • Transthyretin (TTR)
  • N-terminal pro b-type natriuretic peptide (NT-proBNP)
  • NT-proBNP
  • Amyloidosis
  • ATTR-CM
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ATTR-CM with either wild-type or variant TTR genotype
  • End-diastolic interventricular septal wall thickness ≥ 12 mm on echocardiography measured at Screening
  • NT-proBNP > 2000 pg/mL at Screening
  • Treatment with a loop diuretic for at least 30 days prior to Screening
  • History of heart failure Class II-IV at Screening
  • of ≥ 6 months as per the Investigator's judgment
  • Males and females of childbearing ability must use

Exclusion criteria

Exclusion Criteria:

  • Known amyloidosis
  • Known light chain (AL) or secondary amyloidosis (AA), or any other form of systemic amyloidosis
  • Acute coronary syndrome, unstable angina, stroke, , coronary revascularization, cardiac device implantation, cardiac valve repair, or major surgery within 3 months of Screening
  • Uncontrolled cardiac arrhythmia, per Investigator's assessment
  • \< 30% on echocardiography
  • Renal failure requiring dialysis or an \< 20 mL/min/1.73 m2 at Screening
  • Polyneuropathy with PND score IV
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,182 participants (actual)

Study arms

  • Experimental
    ALXN2220

    Participants will receive weight-based dose of ALXN2220 via intravenous (IV) infusion every 4 weeks (q4w) for at least 30 months up to a maximum of 48 months.

    Drug: ALXN2220

  • Placebo comparator
    Placebo

    Participants will receive placebo via IV infusion q4w for at least 30 months up to a maximum of 48 months.

    Drug: Placebo

Interventions

  • Participants will receive ALXN2220 via IV infusion.

  • DrugPlacebo

    Participants will receive placebo via IV infusion.

06

What researchers measure

Primary outcomes

  1. Total Occurrence of ACM and CV clinical events during the Blinded Treatment Period

    Time frame: Baseline up to the end of study (up to Month 48)

Secondary outcomes

  1. Change From Baseline in Kansas City Cardiomyopathy Questionnaire-Overall Score (KCCQ-OS) at Month 30

    Time frame: Baseline, Month 30

  2. Time to CV-related Mortality

    Time frame: Baseline up to the end of study (up to Month 48)

  3. Change from Baseline in Six-minute Walk Test (6MWT) at Month 30

    Time frame: Baseline, Month 30

  4. Total Occurrences of CV Clinical Events

    Time frame: Baseline up to the end of study (up to Month 48)

  5. Time to ACM

    Time frame: Baseline up to the end of study (up to Month 48)

07

Study locations

213 sites
  • Research Site
    Irvine, California 92614, United States
  • Research Site
    La Jolla, California 92037, United States
  • Research Site
    Palo Alto, California 94304, United States
  • Research Site
    San Francisco, California 94143, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Washington D.C., District of Columbia 20010, United States
  • Research Site
    Jacksonville, Florida 32224, United States
  • Research Site
    Weston, Florida 33331, United States
  • Research Site
    Atlanta, Georgia 30309, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Boston, Massachusetts 02118, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    Stony Brook, New York 11794, United States
  • Research Site
    Chapel Hill, North Carolina 27599, United States
  • Research Site
    Durham, North Carolina 27705, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Danville, Pennsylvania 17822, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Greenville, South Carolina 29605, United States
  • Research Site
    Memphis, Tennessee 38120, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Salt Lake City, Utah 84132, United States
  • Research Site
    Falls Church, Virginia 22042, United States
  • Research Site
    Richmond, Virginia 23298, United States
  • Research Site
    Seattle, Washington 98195, United States
  • Research Site
    Madison, Wisconsin 53705, United States
  • Research Site
    Buenos Aires, 1425, Argentina
  • Research Site
    CABA, C1025ABI, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1181ACH, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1428, Argentina
  • Research Site
    Córdoba, X5016KEH, Argentina
  • Research Site
    Bedford Park, 5042, Australia
  • Research Site
    Box Hill, 3128, Australia
  • Research Site
    Brisbane, 4102, Australia
  • Research Site
    Darlinghurst, 2010, Australia
  • Research Site
    Joondalup, 6027, Australia
  • Research Site
    Melbourne, 3004, Australia
  • Research Site
    Westmead, 2145, Australia
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Vienna, 1090, Austria
  • Research Site
    Vienna, 1160, Austria
  • Research Site
    Wels, 4600, Austria
  • Research Site
    Bruges, 8000, Belgium
  • Research Site
    Brussels, 1070, Belgium
  • Research Site
    Genk, 3600, Belgium
  • Research Site
    Aracaju, 49015-380, Brazil
  • Research Site
    Campinas, 13083, Brazil
  • Research Site
    Fortaleza, 60430-375, Brazil
  • Research Site
    Porto Alegre, 90560-030, Brazil
  • Research Site
    Ribeirão Preto, 14026-020, Brazil
  • Research Site
    Ribeirão Preto, 14051-140, Brazil
  • Research Site
    Rio de Janeiro, 20551-030, Brazil
  • Research Site
    Rio de Janeiro, 22270-005, Brazil
  • Research Site
    São Paulo, 01323-001, Brazil
  • Research Site
    São Paulo, 04012-909, Brazil
  • Research Site
    São Paulo, 05403-000, Brazil
  • Research Site
    São Paulo, 05652-900, Brazil
  • Research Site
    Calgary, Alberta T2N 1N4, Canada
  • Research Site
    Winnipeg, Manitoba R2H 2A6, Canada
  • Research Site
    London, Ontario N6A 5A5, Canada
  • Research Site
    Toronto, Ontario M5G 2C4, Canada
  • Research Site
    Chicoutimi, Quebec G7H 5H6, Canada
  • Research Site
    Montreal, Quebec H1T 1C8, Canada
  • Research Site
    Montreal, Quebec H2X 1R9, Canada
  • Research Site
    Rimouski, Quebec G5L 5T1, Canada
  • Research Site
    Beijing, 100034, China
  • Research Site
    Beijing, 100037, China
  • Research Site
    Beijing, 100191, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Changsha, 430033, China
  • Research Site
    Chengdu, 610000, China
  • Research Site
    Chengdu, 610072, China
  • Research Site
    Chongqing, 400042, China
  • Research Site
    Fuzhou, 350005, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Guiyang, 550044, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Harbin, 150080, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Jinan, 250021, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Shanghai, 201114, China
  • Research Site
    Tianjin, 300457, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Prague, 128 08, Czechia
  • Research Site
    Prague, 140 00, Czechia
  • Research Site
    Aarhus, 8200, Denmark

Showing the first 100 of 213 sites across 27 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Beltran J, Bolton S, Patel P, Sharma R. Patient engagement in protocol development for rare disease clinical trials: a framework. Res Involv Engagem. 2026 Oct 9;12(1):167. doi: 10.1186/s40900-026-00985-3. PubMed 42855714 ↗

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2027, 46 months after the start.

Of 25 phase 3 interventional studies under Amyloidosis, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 74. This study's planned 46 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2023
First posted
Dec 28, 2023
StartActual
Jan 11, 2024
Primary completionEst.
Dec 6, 2027
CompletionEst.
Apr 5, 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
1181→1182
Oct 22, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42855714 ↗
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42855714 ↗
    Enrollment 1181→1182
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06183931
Responsible party
Sponsor
First posted
Dec 28, 2023
Start date
Jan 11, 2024
Primary completion
Dec 6, 2027 (estimated)
Completion
Apr 5, 2028 (estimated)
Last update
Oct 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cliramitug

Start the discussion